Pharmacological and biochemical properties of isomeric yohimbine alkaloids.
The stereochemical and pharmacological properties of yohimbine and some of its isomers are briefly reviewed. Several pharmacological and physical properties of a selection of the isomers have been determined with a view to elucidating which might be important in the elaboration of the known behavioral effects produced by them. Activity is not dependent upon lipid solubility or on the ease of access to the central nervous system. The isomers are weak inhibitors of rat-brain acetylcholinesterase and weak antagonists at muscarinic cholinergic receptors. In the rat brain in vitro they do not possess significant monoamine oxidase-inhibiting properties nor do they inhibit the uptake of serotonin. They are relatively potent antagonists of 5HT on the rat isolated fundus preparation and their potency in this preparation may be related to their ability to produce behavioral and cardiovascular effects in man and dogs.
D000818:Animals; D001921:Brain / Q000378:metabolism; D002217:Carbachol / Q000037:antagonists & inhibitors; D002800:Cholinesterase Inhibitors; D007031:Hypothalamus / Q000201:enzymology; D066298:In Vitro Techniques; D008297:Male; D051379:Mice; D008958:Models, Molecular; D008996:Monoamine Oxidase Inhibitors; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D051381:Rats; D012701:Serotonin / Q000378:metabolism; D012702:Serotonin Antagonists; D012995:Solubility; D013574:Synaptosomes / Q000378:metabolism; D015016:Yohimbine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology*
D002800:Cholinesterase Inhibitors; D008996:Monoamine Oxidase Inhibitors; D012702:Serotonin Antagonists; D015016:Yohimbine; D012701:Serotonin; D002217:Carbachol